The scrutiny centers on the June 15, 2026, announcement regarding the Phase 2 AMPLIFY-7P study of ELI-002 7P, a therapy intended for adjuvant pancreatic cancer. Company officials revealed that the trial failed to hit its pre-specified primary endpoint for disease-free survival within the intent-to-treat population. Investors reacted sharply to the disclosure, driving the stock price down by $9.97 to close at $4.08 per share.

Pomerantz LLP is currently examining whether Elicio’s leadership engaged in unlawful business practices or violated securities laws leading up to the trial results. Investors who held stock during this period are encouraged to contact Danielle Peyton at the firm to discuss potential class action participation.